We are in the efficacy stage of this trial. There were enough shRNA delivered to induce a response. There hasn't been enough time to start cohort four without shortening cohort three.
BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-71
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)